Home600535 • SHA
Tasly Pharmaceutical Group Co Ltd
Â¥14.76
Jan 27, 3:59:36 PM GMT+8 · CNY · SHA · Disclaimer
Stock
Previous close
Â¥14.54
Day range
¥14.57 - ¥14.81
Year range
¥12.24 - ¥17.77
Market cap
22.05B CNY
Avg Volume
8.69M
P/E ratio
25.11
Dividend yield
2.79%
Primary exchange
SHA
Market news
Financials
Income Statement
Revenue
Net income
(CNY)Sep 2024Y/Y change
Revenue
2.09B-4.06%
Operating expense
1.03B-2.03%
Net income
179.89M-44.67%
Net profit margin
8.60-42.36%
Earnings per share
——
EBITDA
441.72M-18.76%
Effective tax rate
14.16%—
Total assets
Total liabilities
(CNY)Sep 2024Y/Y change
Cash and short-term investments
4.97B13.35%
Total assets
16.83B-4.76%
Total liabilities
3.82B-22.94%
Total equity
13.02B—
Shares outstanding
1.49B—
Price to book
1.71—
Return on assets
4.92%—
Return on capital
5.52%—
Net change in cash
(CNY)Sep 2024Y/Y change
Net income
179.89M-44.67%
Cash from operations
303.22M22.05%
Cash from investing
-260.81M-362.16%
Cash from financing
-992.53M-2,032.67%
Net change in cash
-951.66M-338.75%
Free cash flow
-824.52M-1,070.21%
About
Tasly is a Chinese pharmaceutical company based in the city of Tianjin. It was established in 1994 and is notably producing traditional Chinese medicines. It has a turnover of 4 billion US dollars, 10,000 employees and is listed on the Shanghai Stock Exchange. In 2009, Chinese pharmacologist Li Lianda claimed that a key product made by Tasly was unsafe. Tasly sued Li in 2013, alleging that Li's claim was baseless and was motivated by his financial and employment relations with Guangzhou Pharmaceutical, a direct competitor of Tasly. In September 2014, the Tianjin High People's Court ruled in favour of Tasly and ordered Li to issue an apology and pay Tasly 300,000 yuan in compensation. In February 2017, Tasly announced plans to form a joint venture with American multi-level marketing company Herbalife. Wikipedia
Founded
1994
Website
Employees
9,223
Search
Clear search
Close search
Google apps
Main menu